5-Monobutyl methotrexate

Overview

5-Monobutyl methotrexate (NSC 305986; γ-MBMTX) is a dihydrofolate reductase ( DHFR ) inhibitor and esterase substrate. 5-Monobutyl methotrexate is hydrolyzed by esterases to produce methotrexate. In rhesus monkeys, 5-Monobutyl methotrexate clears more slowly from cerebrospinal fluid than from serum, and its serum protein binding rate exceeds 99%. At the same dose rate, 5-Monobutyl methotrexate achieves cerebrospinal fluid concentrations comparable to those of Methotrexate ( HY-14519 ), and exhibits activity against Methotrexate -resistant cells (with transport defects) that is comparable to that against sensitive parental cells. 5-Monobutyl methotrexate can be used in studies related to Methotrexate -resistant tumors.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Dihydrofolate reductase (DHFR)

Product Information

• Catalog No.: HY-137357
• CAS No.: 66147-31-7
• Molecular Formula: C24H30N8O5
• Molecular Weight: 510.55
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source